Association between non-alcoholic fatty liver disease and endometrial cancer

Yıl 2022, Cilt: 39 Sayı: 2, 507 - 510, 18.03.2022

Nazlı Topfedaisi Özkan İbrahim Yalçın Mehmet Mutlu Meydanlı

Öz

Metabolic syndrome (MetS) increase the risk of endometrial cancer (EC). Non-alcoholic fatty liver disease (NAFLD) is related with MetS and share many risk factors with EC that may have significant roles in its development; however, the relationship between NAFLD and EC remains unclear. 207 patients who were operated for endometrial cancer in our hospital between 2011 and 2015, and 243 gynecological patients without a history of malignancy who were randomly selected as the control group. NAFLD was diagnosed based on abdominal ultrasonography findings. There was no significant difference presence of diabetes mellitus and ALT, AST levels between EC group and control group. In EC group, age, body masss indeks (BMI), hypertension and NAFLD were significantly higher than those in control group (P < 0.001). Logistic regression analysis showed that age and NAFLD are independent risk factors for presence of EC. Age and NAFLD were a possible independent risk factor for EC in the present study. Therefore, a multi-center and large-population study will be needed to prove our conclusions.

Anahtar Kelimeler

endometrial cancer, non-alcoholic fatty liver disease, obesity, metabolic syndrome

Kaynakça

• 1. Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol. 2013 Jul 10;31(20):2607-18.
• 2. Kim JJ, Chapman-Davis E. Role of progesterone in endometrial cancer. Semin Reprod Med. 2010;28(1):81–90.
• 3. Bjørge T, Engeland A, Tretli S,Weiderpass E. Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. Int J Cancer. 2007 Jan 15;120(2): 378–83.
• 4. Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol. 2013;31(20):2607–18. 5. World Cancer Research Fund. Cancers linked with greater body fatness [Webpage] [Internet], 2015. http://www.wcrf.org/int/cancer-facts-figures/link-between-lifestyle-cancer-risk/cancers-linked- greater-body-fatness (cited 23 Mar 2016).
• 6. Friedenreich CM, Biel RK, Lau DC, Csizmadi I, Coumeya KS, Magliocco AM, et al. Case–control study of the metabolic syndrome and metabolic risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:2384–95.
• 7. Rosato V, Zucchetto A, Bosetti C, Dal Maso L, Montella M, Pelucchi C, et al. Metabolic syndrome and endometrial cancer risk. Ann Oncol. 2011;22:884–9.
• 8. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012;35(11):2402–11.
• 9. Della Corte C, Mosca A, Majo F, Lucidi V, Panera N, Giglioni E, et al. Nonalcoholic fatty pancreas disease and nonalcoholic fatty liver disease: more than ectopic fat. Clin Endocrinol (Oxf). 2015;83:656–62.
• 10. Lee DY, Lee TS. Associations between metabolic syndrome and gynecologic cancer. Obstet Gynecol Sci. 2020 May;63(3):215-224.
• 11. Adambekov S, Yi Y, Fabio A, Miljkovic I, Edwards RP, Lopa S, et al. Metabolic Syndrome in Endometrial Cancer Patients: Systematic Review. Metab Syndr Relat Disord. 2019 Jun;17(5):241-249.
• 12. Arthur RS, Kabat GC, Kim MY, Wild RA, Shadyab AH, Wactawski-Wende J, et al. Metabolic syndrome and risk of endometrial cancer in postmenopausal women: a prospective study. Cancer Causes Control. 2019 Apr;30(4):355-363.
• 13. Wang L, Du ZH, Qiao JM, Gao S. Association between metabolic syndrome and endometrial cancer risk: a systematic review and meta-analysis of observational studies. Aging (Albany NY). 2020 May 22;12(10):9825-9839.
• 14. Jin J, Dalwadi SM, Masand RP, Hall TR, Anderson ML, Ludwig MS. Association Between Metabolic Syndrome and Endometrial Cancer Survival in a SEER-Medicare Linked Database. Am J Clin Oncol. 2020 Jun; 43(6):411-417.
• 15. Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res 2012;2012:145754.
• 16. Singh D, Das CJ, Baruah MP. Imaging of nonalcoholic fatty liver disease: A road less travelled. Indian J Endocrinol Metab 2013; 17: 990-995.
• 17. van Kruijsdijk RC, van der Wall E, Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev 2009;18: 2569-78.
• 18. Zhang Z, Zhou D, Lai Y, Liu Y, Tao X, Wang Q, et al. Estrogen induces endometrial cancer cell proliferation and invasion by regulating the fat mass and obesity-associated gene via PI3K/AKT and MAPK signaling pathways Cancer Lett. 2012 Jun 1;319(1):89-97.
• 19. Arcidiacono B, Iiritano S, Nocera A, Possidente K, Nevolo MT, Ventura V, et al. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res. 2012; 2012:789174.
• 20. Armandi A, Rosso C, Caviglia GP, Bugianesi E. Insulin resistance across the spectrum of nonalcoholic fatty liver disease. Metabolites. 2021 Mar 8;11(3):155.
• 21. Shin SW, Lee SJ. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease . N Engl J Med. 2014 Dec 4;371(23):2236.
• 22. Mantovani A, Petracca G, Beatrice G, Csermely A, Tilg H, Byrne CD, et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut. 2021 Mar 8:gutjnl-2021-324191.
• 23. Tomeno W, Imajo K, Takayanagi T, Ebisawa Y, Seita K, Takimoto T, et al. Complications of Non-Alcoholic Fatty Liver Disease in Extrahepatic Organs. Diagnostics (Basel). 2020 Nov 7;10(11):912.
• 24. Burbos N, Musonda P, Crocker SG, Morris EP, Duncan TJ, Nieto JJ. Outcome of investigations for postmenopausal vaginal bleeding in women under the age of 50 years. Gynecol Oncol. 2012 Apr;125(1):120-3.